ATE320248T1 - Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung - Google Patents

Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung

Info

Publication number
ATE320248T1
ATE320248T1 AT01977759T AT01977759T ATE320248T1 AT E320248 T1 ATE320248 T1 AT E320248T1 AT 01977759 T AT01977759 T AT 01977759T AT 01977759 T AT01977759 T AT 01977759T AT E320248 T1 ATE320248 T1 AT E320248T1
Authority
AT
Austria
Prior art keywords
garcinol
anthocyanin
hca
reduction
composition
Prior art date
Application number
AT01977759T
Other languages
English (en)
Inventor
Muhammed Majeed
Vladimir Badmaev
Original Assignee
Sabinsa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sabinsa Corp filed Critical Sabinsa Corp
Application granted granted Critical
Publication of ATE320248T1 publication Critical patent/ATE320248T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
AT01977759T 2000-08-17 2001-08-17 Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung ATE320248T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22582100P 2000-08-17 2000-08-17

Publications (1)

Publication Number Publication Date
ATE320248T1 true ATE320248T1 (de) 2006-04-15

Family

ID=22846386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977759T ATE320248T1 (de) 2000-08-17 2001-08-17 Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung

Country Status (12)

Country Link
US (1) US7063861B2 (de)
EP (1) EP1254209B1 (de)
JP (2) JP4205943B2 (de)
AT (1) ATE320248T1 (de)
AU (1) AU773081B2 (de)
CA (1) CA2387548A1 (de)
DE (1) DE60118019T2 (de)
DK (1) DK1254209T3 (de)
ES (1) ES2260293T3 (de)
NZ (1) NZ518116A (de)
PT (1) PT1254209E (de)
WO (1) WO2002014477A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA
US20030187055A1 (en) * 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
WO2003092730A1 (en) * 2002-04-30 2003-11-13 Unibar Corporation Hydroxycitric acid salt composition and method of making
US8394856B2 (en) * 2002-07-02 2013-03-12 Glykon Technologies Group, Llc (-)-Hydroxycitric acid for controlling inflammation
WO2004105733A1 (en) * 2003-05-29 2004-12-09 Glykon Technologies Group, Llc Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
WO2005007088A2 (en) * 2003-07-03 2005-01-27 Unibar Corporation Stabilized anthocyanin extract from garcinia indica
US20050009919A1 (en) * 2003-07-07 2005-01-13 Clouatre Dallas L. Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
US20080207952A1 (en) * 2003-10-09 2008-08-28 Muhammed Majeed Novel therapeutic applications of natural poly isoprenylated benzophenone derivatives as drugs/medicaments
US7386111B2 (en) * 2004-02-10 2008-06-10 Vonage Network Inc. Method and apparatus for placing a long distance call based on a virtual phone number
EP1781116A4 (de) 2004-06-04 2009-07-29 Horizon Science Pty Ltd Natürliches süssungsmittel
JP5775656B2 (ja) 2005-06-03 2015-09-09 ホリズン サイエンス ピーティーワイ リミテッド ボディマス再分布性を有する物質
BRPI0715018B1 (pt) 2006-09-19 2021-12-07 The Product Makers (Australia) Pty Ltd Processo de produção de um extrato derivado de cana de açúcar que possui características de redução de índice glicêmico
WO2008049121A2 (en) * 2006-10-19 2008-04-24 Renaissance Herbs, Inc. Hydroxycitric acid compositions, methods of making, and therapeutic uses of same
CN101686963A (zh) * 2007-05-04 2010-03-31 营养保健商业咨询公司 具有脂解活性的组合物，其生产方法及组合物的用途
JP5117762B2 (ja) * 2007-05-18 2013-01-16 株式会社半導体エネルギー研究所 液晶表示装置
US20090062231A1 (en) * 2007-08-31 2009-03-05 O'mara Ann Marie Appetite Suppressant Composition and Method of Appetite Suppression
US20100233306A1 (en) * 2009-03-16 2010-09-16 Sevanti Mehta Methods and compositions for weight loss using garcinia indica fruit puree
WO2012092430A1 (en) * 2010-12-30 2012-07-05 Muhammed Majeed Hepatoprotectant activity of garcinol
US8329743B2 (en) * 2011-01-10 2012-12-11 Sami Labs Limited Compositions and its use in treating obesity or inducing weight loss
WO2012106761A1 (en) 2011-02-08 2012-08-16 Horizon Science Pty Ltd Sugar extracts
JP6239622B2 (ja) 2012-08-28 2017-11-29 ザ プロダクト メーカーズ （オーストラリア） プロプライエタリー リミテッド 抽出方法
CN105722520A (zh) 2013-08-16 2016-06-29 产品制造商（澳大利亚）有限公司 甘蔗衍生提取物及治疗方法
US10285961B2 (en) 2014-02-06 2019-05-14 University Of Houston System Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof
KR101781365B1 (ko) * 2016-08-31 2017-09-25 주식회사 코씨드바이오팜 반응표면분석법을 이용하여 가르시니아 캄보지아로부터 하이드록시 시트르산을 고수율로 추출하는 방법
EP3638226A4 (de) * 2017-06-15 2021-04-07 Sami Labs Limited Potenzial von garcinol gegen adipositas
US11052125B2 (en) * 2018-04-30 2021-07-06 Sami Labs Limited Compositions for weight loss
KR102728051B1 (ko) * 2021-11-26 2024-11-11 주식회사 청안오가닉스 초임계 유체를 이용한 가르시니아 캄보지아로부터 하이드록시 시트르산의 추출방법
GB2623571A (en) * 2022-10-21 2024-04-24 Mootral Innovations Ltd Compositions for reducing methane emission
JP7713751B1 (ja) * 2024-11-19 2025-07-28 株式会社東洋新薬 経口組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
PT815857E (pt) * 1995-12-26 2005-01-31 Suntory Ltd Agente anti-obesidade procianidina como ingrediente activo
JPH10203968A (ja) * 1997-01-27 1998-08-04 Munekazu Iinuma 抗腫瘍剤
JPH10265397A (ja) * 1997-03-25 1998-10-06 Toyotama Kenko Shokuhin Kk 肥満予防剤
JPH111431A (ja) * 1997-06-10 1999-01-06 Nichiyaku Kk 肥満抑制剤
JPH11139965A (ja) * 1997-11-06 1999-05-25 Kikkoman Corp 抗腫瘍薬
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
JP2000072665A (ja) * 1998-08-31 2000-03-07 Kikkoman Corp ヒアルロニダーゼ阻害剤
WO2000012080A1 (en) 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management
FR2790645B1 (fr) * 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
JP2000355536A (ja) * 1999-06-10 2000-12-26 Kikkoman Corp 発癌予防薬
FR2804319B1 (fr) * 2000-01-28 2002-10-25 Clarins Lab Composition cosmetique amincissante comprenant en tant qu'agent actif un extrait de plante contenant de l'anp
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA

Also Published As

Publication number Publication date
JP2008110996A (ja) 2008-05-15
WO2002014477A2 (en) 2002-02-21
AU9685101A (en) 2002-02-25
US20020187943A1 (en) 2002-12-12
DK1254209T3 (da) 2006-07-24
DE60118019T2 (de) 2006-11-02
JP2004506657A (ja) 2004-03-04
CA2387548A1 (en) 2002-02-21
US7063861B2 (en) 2006-06-20
JP4205943B2 (ja) 2009-01-07
DE60118019D1 (de) 2006-05-11
EP1254209B1 (de) 2006-03-15
EP1254209A4 (de) 2004-09-08
ES2260293T3 (es) 2006-11-01
WO2002014477A3 (en) 2002-08-01
NZ518116A (en) 2005-06-24
EP1254209A2 (de) 2002-11-06
PT1254209E (pt) 2006-08-31
AU773081B2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
ATE320248T1 (de) Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung
TW200633695A (en) Methods for purifying trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
DK0832081T3 (da) Bicykliske-aromatiske forbindelser
DE60230961D1 (de) Verwendung einer dihydrochalcon-reichen phenolischen Fraktion für eine kosmetische Behandlung
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0008865A (pt) Composições contendo fluoreto estanhoso para o tratamento de dentes hipersensìveis
ATE198467T1 (de) Diaromatische propynyl- oder dienylverbindungen
DE60215648D1 (de) Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
FR2836630B1 (fr) Utilisation cosmetique de la phytosphingosine comme agent amincissant et compositions cosmetiques contenant de la phytosphingosine
BRPI0418854A (pt) composições herbáceas
BR0315374A (pt) Compostos orgânicos
DE50210605D1 (de) Gewürzkrautzubereitung
DE60330345D1 (de) Verwendung von ginkgo biloba extrakten zur förderung der muskelmasse zum nachteil der fettmasse
SE9803156D0 (sv) A new composition
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
TW200505918A (en) Azaquinazoline derivatives
UA32384A (uk) Спосіб лікування пародонтиту
TW200602057A (en) Medicaments containing n-sulfamoyl-n' -arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254209

Country of ref document: EP